“Encouraging” Oxford coronavirus vaccine results prompt 100 million orders from the UK
Research suggests that the Oxford coronavirus vaccine, manufactured by AstraZeneca, demonstrates a “strong” immune response in adults, aged 60 to 70.
These findings, based on 560 healthy adult volunteers, increase optimism that the vaccine can protect the age groups most at risk from coronavirus, which researchers state is “encouraging”.
Oxford’s data is from the earlier stages of testing which examine the safety of the vaccine and the body’s response to it.
Through larger, phase three trials, the aim is to discover whether the vaccine prohibits people from developing Covid-19. There are expectations that in the upcoming weeks, the early findings from this essential phase will release.
Already, the vaccines Moderna, Pfizer-BioNTech and Sputnik have reported sufficient preliminary data from phase three trials. American multinational pharmaceutical corporation, Pfizer, even suggests that their vaccine could protect 94 per cent of people aged 65 and over from Coivd-19.
However, ultimately, the Oxford vaccine may be the one that gets distributed, due to it not needing storing at as cold temperatures as the other vaccines.
The UK Government has even ordered 100 million doses of the Oxford vaccine, which is more than any of the others: 40 million doses of the Pfizer-BioNTech vaccine and five million of the Moderna vaccine.
The study’s lead, Professor Andrew Pollard of the University of Oxford, states that he was “absolutely delighted with the results”, which demonstrated a strong immune response “even in those over 70 years of age”.